Patients taking clopidogrel with either one or two CYP2C19 LoF alleles were significantly associated with MACE compared to those with no LoF alleles (P = 2.97 × 10-27, OR = 1.53, 95% CI = 1.42–1.65), including MI (P = 2.09 × 10-31, OR = 3.98, 95% CI = 3.15–5.02), UA (P = 7.24 × 10-13, OR = 1.88, 95% CI = 1.58–2.23), HF (P = 1.77 × 10-4, OR = 1.37, 95% CI = 1.22–1.55), TVR (P = 1.91 × 10-4, OR = 1.29, 95% CI = 1.13–1.47), and stroke (P = 6.31 × 10-5, OR = 1.41, 95% CI = 1.19–1.67) under multivariate analysis (Fig. 3a and Supplementary Table 5). Here, CYP2C19 is linked to stroke disorder.